On September 20, 2024, the Food and Drug Administration sanctioned isatuximab-irfc (Sarclisa, Sanofi-Aventis U.S. LLC) in conjunction with bortezomib, lenalidomide, and dexamethasone for people with...
On September 19, 2024, the Food and Drug Administration sanctioned amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) in conjunction with carboplatin and pemetrexed for adult patients diagnosed with ...
On September 17, 2024, the Food and Drug Administration authorized pembrolizumab (Keytruda, Merck) in conjunction with pemetrexed and platinum-based chemotherapy as the initial treatment for unresec...
On September 17, 2024, the Food and Drug Administration approved ribociclib (Kisqali, Novartis Pharmaceuticals Corporation) in conjunction with an aromatase inhibitor for the adjuvant therapy of adult...
On September 12, 2024, the Food and Drug Administration sanctioned atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) for subcutaneous administration for all adult indications co...
Understanding TIL TherapyTIL is an immunotherapy method that uses one's body's immune system to fight cancer. It begins by harvesting lymphocytes-a type of white blood cell-that infiltrate a tumor, ex...
Understanding CAR T Cell therapyCAR T-cell therapy involves modifying the T cells from a patient, which are part of the immune system, to carry receptors that specifically target cancer cells. Once th...
Understanding pancreatic cancerPancreatic cancer is recognized as one of the most aggressive and lethal cancers, largely due to the fact that it tends to be diagnosed at a late stage. The pancreas, a ...
GBMThe glioblastoma multiforme (GBM) is considered the most aggressive and lethal type of brain tumor. Despite treatments that include surgery, radiation, and chemotherapy, it has an unfavorable progn...
Acute myeloid leukemia (AML)Acute Myeloid Leukemia (AML) is a critical and aggressive form of blood cancer that necessitates advanced treatment options for better patient outcomes. Recently, CAR T Cel...